U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07259317) titled 'Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma' on Nov. 03.
Brief Summary: This is a Phase 2, single-arm study to evaluate the safety and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (PDAC).
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Adenocarcinoma
Carcinoma, Pancreatic Ductal
Intervention:
DRUG: Relacorilant 150 mg once daily (QD)
Relacorilant will be administered as capsules for oral dosing on the day before (excluding Cycle 1, Day -1), the d...